Live Breaking News & Updates on Kyahn Williamson|Page 1

Stay updated with breaking news from Kyahn williamson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Telix Pharmaceuticals Limited: Telix Completes TLX250-CDx (Zircaix®) BLA Submission for Kidney Cancer Imaging

MELBOURNE, Australia, June 3, 2024 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has completed the submission of a Biologics License Application ....

United States , Kyahn Williamson , Cdx Zircaix , James Stonecypher , Australian Therapeutic Goods Administration , Telix Pharmaceuticals Limited , Cdx International Expanded Access , Australian Securities Exchange , Drug Administration , Telix Pharmaceuticals Limited Disclosure Committee , Health Canada , Corporate Communications , Telix Pharmaceuticals , Prnewswire Telix Pharmaceuticals Limited , Pharmaceuticals Limited , Biologics License Application , Priority Review , Breakthrough Therapy , Chief Development Officer , International Expanded , Offering Compassionate Use , Investigational Medicines , Ihr Portfolio ,

Telix Completes TLX250-CDx (Zircaix™) BLA Submission for Kidney Cancer Imaging

Telix Completes TLX250-CDx (Zircaix™) BLA Submission for Kidney Cancer Imaging
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United States , Cdx Zircaix , Kyahn Williamson , James Stonecypher , Cdx International Expanded Access , Telix Pharmaceuticals Limited Disclosure Committee , Health Canada , Australian Securities Exchange , Drug Administration , Telix Pharmaceuticals Limited , Australian Therapeutic Goods Administration , Corporate Communications , Telix Pharmaceuticals , Kidney Cancer , Pharmaceuticals Limited , Biologics License Application , Priority Review , Breakthrough Therapy , Chief Development Officer , International Expanded , Offering Compassionate Use , Investigational Medicines ,

Telix Completes TLX250-CDx (Zircaix™) BLA Submission for

MELBOURNE, Australia, June 03, 2024 (GLOBE NEWSWIRE) Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has. ....

United States , James Stonecypher , Kyahn Williamson , Cdx Zircaix , Telix Pharmaceuticals Limited , Cdx International Expanded Access , Telix Pharmaceuticals Limited Disclosure Committee , Australian Therapeutic Goods Administration , Health Canada , Corporate Communications , Telix Pharmaceuticals , Drug Administration , Australian Securities Exchange , Pharmaceuticals Limited , Biologics License Application , Priority Review , Breakthrough Therapy , Chief Development Officer , International Expanded , Offering Compassionate Use , Investigational Medicines ,

Telix Pharmaceuticals Limited: Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer

TLX591 is an investigational anti-PSMA[1] radio-antibody-drug conjugate (rADC) therapy being developed for the treatment of mCRPC, differentiated by a short two-week dosing regimen.Reported ....

United States , Nat Lenzo , Kyahn Williamson , Davidn Cade , Nuclear Oncologist , Telix Pharmaceuticals , Drug Administration , Telix Pharmaceuticals Limited Disclosure Committee , Health Canada , Telix Pharmaceuticals Limited , Australian Therapeutic Goods Administration , Corporate Communications , Australian Securities Exchange , Prnewswire Telix Pharmaceuticals Limited , Pharmaceuticals Limited , General Internal Medicine Physician , Group Chief Medical Officer , Nuc Med , Ihr Portfolio ,

Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer

TLX591 is an investigational anti-PSMA[1] radio-antibody-drug conjugate rADC therapy being developed for the treatment of mCRPC differentiated by a short two-week dosing regimen Reported median radiographic progression-free survival rPFS is 88 months Builds on prior data from the ProstACT SELECT[2] trial demonstrating favourable safety profile and biodistribution[3] MELBOURNE Australia May 31 2024 PRNewswire Telix Pharmaceuticals Limited ASX TLX Telix the Company today announces additional positive datafrom the ProstACT SELECT trial SELECT of TLX591 177Lu rosopatamab tetraxetan a lutetium-labelled rADC therapy for the treatment of adult patients with PSMA-positive metastatic castrate-resistant prostate cancer mCRPC SELECT is a radiogenomics study intended to evaluate lesion concordance between 68Ga gallium-based PSMA-PET[4] imaging and TLX591 dosimetry for the purpose of validating PET imaging for patient selection for rADC therapy The Company has previously reported final safety data ....

United States , Kyahn Williamson , Davidn Cade , Nat Lenzo , Health Canada , Telix Pharmaceuticals Limited , Australian Securities Exchange , Telix Pharmaceuticals Limited Disclosure Committee , Corporate Communications , Drug Administration , Telix Pharmaceuticals , Nuclear Oncologist , Australian Therapeutic Goods Administration , General Internal Medicine Physician , Group Chief Medical Officer , Nuc Med ,